Neuropathic Pain: Delving Into the Oxidative Origin and the Possible Implication of Transient Receptor Potential Channels
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Job Posting Clinical Microbiology Final
The Department of Pathology & Cell Biology at Columbia University Irving Medical Center (CUIMC) is recruiting for an MD, MD/PhD, or PhD academic clinical microbiologist of any rank to join our faculty as a Medical Director of the NewYork-Presbyterian/CUIMC Clinical Microbiology Laboratory. Applicants should have an established track record of accomplishment within the field of clinical microbiology and a demonstrated ability to lead an experienced group of laboratory technologists, supervisors, and staff. In addition to strong clinical and technical skills, particular emphasis is placed on candidates with a demonstrated record of collegiality and inter-departmental collaboration. Applicants must have completed a fellowship in clinical microbiology and be board-certified/board-eligible in Medical and Public Health Microbiology through the American Board of Medical Microbiology (ABMM) or board-certified/board- eligible in Clinical Pathology with subspecialty certification in Medical Microbiology through the American Board of Pathology (ABP). The applicant must also be able to satify clinical licensing requirements to serve as a Laboratory Director in New York State. The successful applicant will help oversee diagnostic testing in the areas of Bacteriology, Virology, Mycobacteriology, Mycology, and Parasitology. The position also includes responsibilities for teaching of pathology residents, medical students, infectious diseases fellows, and technical staff. Applicants must be currently involved in ongoing research with a track record of publications in the field. The position offers a competitive salary commensurate with training and experience, and an appointment to the faculty of the Columbia University Vagelos College of Physicians & Surgeons. The Clinical Microbiology Laboratory at NewYork-Presbyterian/CUIMC is located in the Washington Heights neighborhood of New York City, offering unparalleled opportunities to work and live in a thriving, diverse, metropolitan environment with access to world-class cultural institutions, restaurants, and entertainment. -
Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug
Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 23, 2021 page 1 nd Interaction with the Human Multidrug Multidrug Human the with nd Interaction This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. -
Supplementary Information
Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262 -
Printable Version
Clinical Pathology Laboratories Drugs of Abuse Testing Offering our clients state-of-the-art testing is part of CPL’s ongoing commitment to excellence. Effective 06/18/2018, Clinical Pathology Laboratories (CPL) will replace current drug of abuse (DAU) screening and screening with reflex confirmation profiles. The new profiles provide: • Reformulation and recombination of classes for profile testing, more relevant to current societal trends • Standardization of drug thresholds to high sensitivity cutoff values • Addition of the following analytes in specific profiles for testing: o Fentanyl o Buprenorphine o 6-Acetylmorphine o MDMA (Ecstasy) • Expansion of testing for adulterants with disqualifying comments added to specimens determined to be altered • Expansion of interpretive notes on reports regarding the method, cutoff values, and specific drugs that may or may not be detected by the screening method New Profile Name EtOH Opiates Cocaine Fentanyl Oxycodone Order Code Methadone Barbiturates Cannabinoids Phencyclidine Acetylmorphine Buprenorphine Amphetamines MDMA/Ecstasy - Benzodiazepines 6 Drug of Abuse, 8 Analytes 3305 X X X X X X X X No Confirm Drug of Abuse, 8 Analytes 3306 X X X X X X X X w/ Confirm Drug of Abuse, 9 Analytes 3316 X X X X X X X X X w/ EtOH, No Confirm Drug of Abuse, 9 Analytes 3315 X X X X X X X X X w/ EtOH, w/ Confirm Drug of Abuse, 9 Analytes 3307 X X X X X X X X X No THC or Confirm Drug of Abuse, 9 Analytes 3308 X X X X X X X X X No THC, w/ Confirm Drug of Abuse, 10 Analytes 3317 X X X X X X X X X X No Confirm -
Clinical Pathology, Immunopathology and Advanced Vaccine Technology in Bovine Theileriosis: a Review
pathogens Review Clinical Pathology, Immunopathology and Advanced Vaccine Technology in Bovine Theileriosis: A Review Onyinyechukwu Ada Agina 1,2,* , Mohd Rosly Shaari 3, Nur Mahiza Md Isa 1, Mokrish Ajat 4, Mohd Zamri-Saad 5 and Hazilawati Hamzah 1,* 1 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang 43400, Malaysia; [email protected] 2 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria Nsukka, Nsukka 410001, Nigeria 3 Animal Science Research Centre, Malaysian Agricultural Research and Development Institute, Headquarters, Serdang 43400, Malaysia; [email protected] 4 Department of Veterinary Pre-clinical sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang 43400, Malaysia; [email protected] 5 Research Centre for Ruminant Diseases, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang 43400, Malaysia; [email protected] * Correspondence: [email protected] (O.A.A.); [email protected] (H.H.); Tel.: +60-11-352-01215 (O.A.A.); +60-19-284-6897 (H.H.) Received: 2 May 2020; Accepted: 16 July 2020; Published: 25 August 2020 Abstract: Theileriosis is a blood piroplasmic disease that adversely affects the livestock industry, especially in tropical and sub-tropical countries. It is caused by haemoprotozoan of the Theileria genus, transmitted by hard ticks and which possesses a complex life cycle. The clinical course of the disease ranges from benign to lethal, but subclinical infections can occur depending on the infecting Theileria species. The main clinical and clinicopathological manifestations of acute disease include fever, lymphadenopathy, anorexia and severe loss of condition, conjunctivitis, and pale mucous membranes that are associated with Theileria-induced immune-mediated haemolytic anaemia and/or non-regenerative anaemia. -
Put Microrna Drug Discovery
Research Collection Doctoral Thesis Gene circuit based screening assays for mirna drug discovery Author(s): Häfliger, Benjamin Publication Date: 2016 Permanent Link: https://doi.org/10.3929/ethz-a-010651992 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH NO. 23325 GENE CIRCUIT BASED SCREENING ASSAYS FOR MIRNA DRUG DISCOVERY A thesis submitted to attain the degree of DOCTOR OF SCIENCES of ETH ZURICH (Dr. sc. ETH Zurich) presented by BENJAMIN HÄFLIGER MSc ETH Biotech, ETH Zurich born on 25.02.1988 citizen of Fischbach, LU accepted on the recommendation of Prof. Dr. Yaakov Benenson Prof. Dr. Sven Panke Dr. Helge Grosshans 2016 ii Abstract Drug discovery is the process of identifying potential new medicines. A key step in this process is high throughput screening (HTS), whereby active compounds are identified from a large library of up to one million candidate molecules. Through minia- turization and automation, such libraries can nowadays be tested in a single week. Despite this impressive performance, about 50% of the screening campaigns fail to provide the desired hits, or the emerging lead compounds do not perform as expected in clinical settings, mostly due to toxicity from off-target interactions. To overcome this issue, novel HTS assays should provide more detailed information on the underlying biology and the relevant off-targets. Multiplexed assays based on liquid chromatog- raphy-mass spectroscopy or deep sequencing could deliver this information; yet, their throughput is comparably low. -
Overview of Pathology and Its Related Disciplines - Soheir Mahmoud Mahfouz
MEDICAL SCIENCES – Vol.I -Overview of Pathology and its Related Disciplines - Soheir Mahmoud Mahfouz OVERVIEW OF PATHOLOGY AND ITS RELATED DISCIPLINES Soheir Mahmoud Mahfouz Cairo University, Kasr El Ainy Hospital, Egypt Keywords: Pathology, Pathology disciplines, Pathology techniques, Ancillary diagnostic methods, General Pathology, Special Pathology Contents 1. Introduction 1.1 Pathology coverage 1.1.1 Etiology and Pathogenesis of a Disease 1.1.2 Manifestations of Disease (Lesions) 1.1.3 Phases Of A Disease Process (Course) 1.2 Physician’s approach to patient 1.3 Types of pathologists and affiliated specialties 1.4 Role of pathologist 2. Pathology and its related disciplines 2.1 Cytology 2.1.1 Cytology Samples 2.1.2 Technical Aspects 2.1.3 Examination of Sample and Diagnosis 3. Pathology techniques and ancillary diagnostic methods 3.1 Macroscopic pathology 3.2 Light Microscopy 3.3 Polarizing light microscopy 3.4 Electron microscopy (EM) 3.5 Confocal Microscopy 3.6 Frozen section 3.7 Cyto/histochemistry 3.8 Immunocyto/histochemical methods 3.9 Molecular and genetic methods of diagnosis 3.10 Quantitative methods 4. Types of tests used in pathology 4.1 DiagnosticUNESCO tests – EOLSS 4.2 Quantitative tests 4.3 Prognostic tests 5. The scope of SAMPLEpathology & its main divisions CHAPTERS 6. Conclusions Glossary Bibliography Biographical sketch Summary Pathology is the science of disease. It deals with deviations from normal body function and ©Encyclopedia of Life Support Systems (EOLSS) MEDICAL SCIENCES – Vol.I -Overview of Pathology and its Related Disciplines - Soheir Mahmoud Mahfouz structure. Many disciplines are involved in the study of disease, as it is necessary to understand the complex causes and effects of various disorders that affect the organs and body as a whole. -
American Society for Clinical Pathology to the Clinical Laboratory Improvement Advisory Committee
Statement from the American Society for Clinical Pathology to the Clinical Laboratory Improvement Advisory Committee The American Society for Clinical Pathology is pleased to provide this statement to the Clinical Laboratory Improvement Advisory Committee (CLIAC) on the roles, responsibilities and competencies of bioinformaticists. The completion of the Human Genome Project has resulted in vast sums of patient data, and bioinformaticists are increasingly being utilized by clinical laboratories to manage, process, and analyze it, especially in the rapidly expanding specialty of molecular diagnostics. Bioinformaticists, and the unique skills these individuals bring, are also helping to transform the practice of pathology and laboratory medicine by developing or/or enhancing the bioinformatics tools used to expand the ability of pathology and laboratory medicine to protect patient health. ASCP greatly appreciates CLIAC’s leadership by focusing attention on the valuable contribution these professionals are making and to improve their ability to do so. The following comments are based on comments provided by our membership during our efforts to respond to the questions posed by the CLIAC. CLIAC Discussion Questions: Question 1: Are Bioinformaticists needed in clinical and public health laboratories? If so, what are the current roles, responsibilities, and competencies of bioinformaticists in these settings? ASCP believes that bioinformaticists are a key component of high quality, full service clinical laboratories, though the roles and responsibilities of these professionals may vary significantly. Informaticists are critical to building the bioinformatics pipeline, which can include the software and database engineering, configuration of available bioinformatics software, and/or management and interfacing of LIS and other informatics systems, both internally within the laboratory (e.g. -
PRODUCT MONOGRAPH Przuacta™
PRODUCT MONOGRAPH PrZUACTA™ zucapsaicin cream, 0.075% w/w Topical Analgesic sanofi-aventis Canada Inc. Date of Preparation: 2150 St. Elzear Blvd. West November 30, 2010 Laval, Quebec H7L 4A8 Submission Control No: 141787 s-a Version 1.1 dated January 7, 2011 PrZUACTA™ Product Monograph Page 1 of 21 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................5 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION................................................................................8 OVERDOSAGE ..................................................................................................................8 ACTION AND CLINICAL PHARMACOLOGY ..............................................................8 STORAGE AND STABILITY............................................................................................9 SPECIAL HANDLING INSTRUCTIONS -
2021 Anatomic & Clinical Pathology
BEAUMONT LABORATORY 2021 ANATOMIC & CLINICAL PATHOLOGY Physician Biographies Expertise BEAUMONT LABORATORY • 800-551-0488 BEAUMONT LABORATORY ANATOMIC & CLINICAL PATHOLOGY • PHYSICIAN BIOGRAPHIES Peter Millward, M.D. Mitual Amin, M.D. Chief of Clinical Pathology, Beaumont Health Interim Chair, Pathology and Laboratory Medicine, Interim Chief of Pathology Service Line, Beaumont Health Royal Oak Interim Physician Executive, Beaumont Medical Group Interim Chair, Department of Pathology and Laboratory Medicine, Oakland University William Beaumont School Interim System Medical Director, Beaumont Laboratory of Medicine Outreach Services Board certification Associate Medical Director, Blood Bank and • Anatomic and Clinical Pathology, Transfusion Medicine, Beaumont Health American Board of Pathology Board certification Additional fellowship training • Anatomic and Clinical Pathology, • Surgical Pathology American Board of Pathology Special interests Subspecialty board certification • Breast Pathology, Genitourinary Pathology, • Blood Banking and Transfusion Medicine, Gastrointestinal Pathology American Board of Pathology Lubna Alattia, M.D. Kurt D. Bernacki, M.D. Cytopathologist and Surgical Pathologist, Trenton System Medical Director, Surgical Pathology Board certification Beaumont Health • Anatomic and Clinical Pathology, Chief, Pathology Laboratory, West Bloomfield American Board of Pathology Breast Care Center Subspecialty board certification Diagnostic Lead, Pulmonary Tumor Pathology • Cytopathology, American Board of Pathology Diagnostic -
Pathology: a Career in Medicine the Study of the Nature of Disease, Its Causes, Processes, Development, and Consequences
PATHOLOGY A Career in Medicine The Intersociety Council for Pathology Information (ICPI) www.pathologytraining.org 2015 Pathology: A Career in Medicine The study of the nature of disease, its causes, processes, development, and consequences. Pathology is the medical specialty that provides a scientific foundation for medical practice The pathologist is a physician who specializes in the diagnosis and management of human disease by laboratory methods. Pathologists function in three broad areas: as diagnosticians, as teachers, and as investigators. Fundamental to the discipline of pathology is the need to integrate clinical information with physiological, biochemical and molecular laboratory studies, together with observations of tissue alterations. Pathologists in hospital and clinical laboratories practice as consultant physicians, developing and applying knowledge of tissue and laboratory analyses to assist in the diagnosis and treatment of individual patients. As teachers, they impart this knowledge of disease to their medical colleagues, to medical students, and to trainees at all levels. As scientists, they use the tools of laboratory science in clinical studies, disease models, and other experimental systems, to advance the understanding and treatment of disease. Pathology has a special appeal to those who enjoy solving disease-related problems, using technologies based upon fundamental sciences ranging from biophysics to molecular genetics, as well as tools from the more traditional disciplines of anatomy, biochemistry, pharmacology, physiology and microbiology. The Pathologist in Patient Care The pathologist uses diagnostic and screening tests to identify and interpret the changes that characterize different diseases in the cells, tissues, and fluids of the body. Anatomic pathology involves the analysis of the A biosample robot prepares specimens for gross and microscopic structural changes caused by testing disease in tissues and cells removed during biopsy procedures, in surgery, or at autopsy. -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9